Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation by ���������
Kaushik et al. Cell Communication and Signaling           (2019) 17:12 
https://doi.org/10.1186/s12964-019-0322-xRESEARCH Open AccessLow dose radiation regulates BRAF-induced
thyroid cellular dysfunction and
transformation
Neha Kaushik1†, Min-Jung Kim2†, Nagendra Kumar Kaushik3, Jae Kyung Myung4, Mi-Young Choi1, Jae-Hyeok Kang1,
Hyuk-Jin Cha5, Cha-Soon Kim6, Seon-Young Nam7* and Su-Jae Lee1,8*Abstract
Background: The existence of differentiated thyroid cells is critical to respond radioactive iodide treatment strategy
in thyroid cancer, and loss of the differentiated phenotype is a trademark of iodide-refractive thyroid disease. While
high-dose therapy has been beneficial to several cancer patients, many studies have indicated this clinical benefit
was limited to patients having BRAF mutation. BRAF-targeted paired box gene-8 (PAX8), a thyroid-specific
transcription factor, generally dysregulated in BRAF-mutated thyroid cancer.
Methods: In this study, thyroid iodine-metabolizing gene levels were detected in BRAF-transformed thyroid cells
after low and high dose of ionizing radiation. Also, an mRNA-targeted approach was used to figure out the
underlying mechanism of low (0.01Gyx10 or 0.1Gy) and high (2Gy) radiation function on thyroid cancer cells after
BRAFV600E mutation.
Results: Low dose radiation (LDR)-induced PAX8 upregulation restores not only BRAF-suppressive sodium/iodide
symporter (NIS) expression, one of the major protein necessary for iodine uptake in healthy thyroid, on plasma
membrane but also regulate other thyroid metabolizing genes levels. Importantly, LDR-induced PAX8 results in
decreased cellular transformation in BRAF-mutated thyroid cells.
Conclusion: The present findings provide evidence that LDR-induced PAX8 acts as an important regulator for
suppression of thyroid carcinogenesis through novel STAT3/miR-330-5p pathway in thyroid cancers.
Keywords: Low dose radiation, LDR, Thyroid cancer, Paired-box domain 8, PAX8, miR-330-5p, Thyroglobulin, TGBackground
Recently activating somatic mutations in the BRAF
proto-oncogene has been discovered in various malig-
nancies, such as in melanoma (60–70% of cases) [1, 2],
colon cancer (10%) [3, 4] including thyroid cancer
(35–70%) [5, 6]. Thyroid tumors are the most frequent neo-
plasms of the endocrine system [7]. Well-differentiated thy-
roid carcinomas account for > 85% of all thyroid cancers
including papillary and follicular carcinomas. In early 2003,
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(http://creativecommons.org/publicdomain/zeoccurrence ranging from 25 to 42% [8]. Papillary thyroid
carcinoma (PTC) and anaplastic thyroid carcinoma (ATC)
have only been reported with these mutations [8], however
it has not been identified in follicular thyroid carcinoma
(FTC), or benign thyroid adenomas [9]. Among all thyroid
subtypes, PTC is the most prevalent and have an aggressive
behavior [10], while undifferentiated anaplastic thyroid car-
cinoma accounts for 3 to 5% of all thyroid cancers [11].
BRAF is a serine/threonine kinases belongs to the RAF
family. RAF proteins are part of the RAF-MEK-ERK path-
way [mitogen activated protein (MAP)/extracellular signal-
regulated kinase (ERK) kinase], a prominently conserved
signaling component in eukaryotes. Once activated through
binding to RAS in its GTP-bound state, RAF kinases
phosphorylate MEK, thereby phosphorylates and acti-
vates ERK [12]. Activation of BRAF has originated asle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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oma [5, 6, 13]. A trans-version from thymine to adenine
(T1799A), leading to a Glu for Val substitution at residue
600 (V600E), accounts for > 92% of BRAF mutations in
thyroid carcinomas [9]. Consistent with a pivotal role in
thyroid cancer initiation, BRAFV600E mutation has been
identified in microcarcinomas [9], and it was revealed to
induce transformed features in thyroid follicular cells
in culture conditions [14]. A recent report suggests
that ultraviolet radiation accelerates BRAF-driven me-
lanogenesis by targeting TP53 [15]. Given that above
well-characterized role of BRAF mutations prompted
us to explore the functions of low dose of ionizing radi-
ation (LDR) in BRAF-mediated cellular transformation in
thyroid cancer cells. The advance of interventional radi-
ology has attracted growing interest in the biological effect
of LDR below 0.1Gy doses [16]. From our previous stud-
ies, it has become apparent that the LDR has the potential
to block KRAS-driven cellular transformation [17] and
metastatic cancer progression in breast cancer cells [18].
As, most of the thyroid patients can be cured with
surgical treatment together with radioactive iodide,
however BRAF-mutated thyroid cancer cells have
lower expression of sodium/iodide symporter (NIS),
thyroid transcription factors (TTF-1 and TTF-2), and
thyroglobulin (TG) than those cells having wild-type
(WT) BRAF [19], and are particularly refractory to
radioiodine therapy [20]. The ability of differentiated
thyroid cells to accumulate iodide is clinically highly
relevant as it makes feasible for thyroid cancer pa-
tients to be treated with ablative doses of radioactive
iodide after stimulation by thyroid-stimulating hor-
mone [21]. Thus, the maintenance of the thyroid dif-
ferentiated phenotype during tumor transformation
has a critical impact in thyroid cancer patient’s sur-
vival [22]. PAX8, a member of the paired box (PAX)
family of transcription factors are required for the
maintenance of the thyroid differentiated phenotype
[23]. Along with the other thyroid transcription fac-
tors TTF-2 and TTF-1, PAX8 is intricate in develop-
ment of thyroid follicular cells as well as expression of
thyroid-specific genes such as the NIS, and TG [24, 25].
These genes are essential for thyroid differentiation as
they mediate the metabolism of iodide, leading to the syn-
thesis of active thyroid hormone. One of the most import-
ant and well-established transcriptional targets of PAX8
is NIS. This symporter is a central plasma membrane
protein that mediates active iodide transport in the thy-
roid and other tissues [26]. In the healthy thyroid cells,
NIS-mediated iodide uptake is the first step in thyroid
hormone biosynthesis. Therefore, loss of the thyroid
differentiated phenotype, particularly loss of NIS func-
tion, is one of the most important hallmarks of thyroid
cancer progression.The purpose of this study was to compare the iodine
metabolizing genes expression profile induced by expres-
sion of BRAFV600E in thyroid cells using LDR. Given that
several miRNAs were associated with less differentiated
tumors [27], here, we took a unified approach based on
the existence of the miRNAs for LDR influence in thyroid
carcinoma. Here, we investigated the restorability of thy-
roid specific genes expression by suppression of the
miR-330-5p in PTC/ATC after LDR exposure. These find-
ings could provide the positive role of LDR in thyroid cells
expressing BRAF-mutant and to characterize those miR-
NAs involved in the alteration of genes essential for thy-
roid differentiation, namely PAX8.
Materials and methods
Chemicals and antibodies
Antibodies specific to pJAK1(Tyr1022/1023), JAK1,
pJAK2(Tyr1007/1008), JAK2, STAT3 and BRAF were
obtained from Santa Cruz Biotechnology, Inc. Anti-
bodies to pSTAT3 (Tyr705) were purchased from Cell
Signaling Technology. PAX8 antibody was purchased
from Abcam (Seoul, Korea). NIS antibody was obtained
from GeneTex, Inc., whereas 4,6-Diamidino-2-pheny-
lindole (DAPI) and β-actin were obtained from Sigma,
Korea. Anti-mouse or rabbit Alexa Fluor 488 and anti-
rabbit or mouse Alexa Fluor 546 were purchased from
Invitrogen. All controls, silencing RNA, micro RNAs
mimics and inhibitor were bought from Genolution
Pharmaceuticals, Inc., Korea. All primers including
control and microRNA primers were designed and
purchased from Macrogen, Korea. Hanks’ Balanced
Salt solution (HBSS), HEPES, Ammonium cerium (IV)
sulphate, Sodium arsenite (III) and sodium iodide
were purchased from Sigma-Aldrich, Korea. The up-
take buffer consisted of HBSS supplemented with
HEPES (10 mM final conc.) was freshly prepared prior
to assay.
Cell culture and transfection
Human thyroid normal follicular N-thy ori-3-1, BHP
10–3, SNU-80, BCPAP, 850-5C and SNU-790 thyroid
cancer cell lines were kindly gifted by Dr. Min-Jung
Kim (KIRAMS, Korea). 850-5C cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) with
high glucose (Hyclone, Korea) whereas other cell lines
were cultured in Roswell park memorial institute
medium (RPMI-1640). Normal thyroid cells were sup-
plemented with 20 mM glutamine (Gibco, Korea). All
cell cultures were supplemented with 10% fetal bovine
serum (Hyclone) and maintained at 37 °C in a 5% CO2
atmosphere. Cells were passaged every two-three day
and often treated with plasmocin™ (Invivogen) to pre-
vent mycoplasma contamination. We used all cell lines
about 25–30 passages to perform our experiments.
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ent cells using Lipofectamine 2000 Reagent (Invitro-
gen, USA) according to the manufacturer’s protocol.
BRAFV600E virus supernatant was made by Min-Jung
Kim (KIRAMS, Korea) and treated directly to normal
thyroid cells at a confluency of 75–80%.
Irradiation
Thyroid cells were plated in 60-mm cell culture dishes
and irradiated with a 137Cs laboratory γ-irradiator
(LDI-KCCH 137, Seoul, Korea) using same procedure
as described in our report previously [18].
Western blot analysis
For Western blotting analysis, cells were harvested and
lysed for protein extraction using cell lysis buffer [40mM
Tris-HCl (pH 8.0), 120mM NaCl, 0.1% Nonidet-P40] sup-
plemented with protease inhibitors. Proteins samples were
separated by SDS-PAGE and blotted onto nitrocellulose
membranes (Amersham, IL), blocked in 5% skim milk for
1 h (h) at room temperature and incubated with the pri-
mary antibodies overnight at 4 °C: anti-BRAF (1:1000),
and anti-β-actin (1:1000). The blots were developed using
horseradish peroxidase-conjugated secondary antibodies
at room temperature for 2 h and visualized using en-
hanced chemiluminescence (ECL) procedures.
Real time PCR analysis
Cell samples RNA was extracted using the Trizol reagent
(Ambion). Quantification of RNA was done using the
NanoDrop™ Spectrophotometer according to the manufac-
turer’s protocol. All qRT-PCR reactions were determined
using the KAPA SYBR FAST qPCR kit from KAPA Biosys-
tems (Wilmington, MA, USA). Amplification reactions
were carried out in a Rotor Gene Q (Qiagen, Korea), and
results were expressed as the fold change calculated by the
ΔΔCt method relative to the control sample. β-actin was
used for normalization as a control. For miRNA analysis,
U6 small nuclear RNA was used as a control to determine
relative miRNA expression.
Tissue samples and immunohistochemistry
Paraffin blocks and slides from 10 cases of PTC and 4
cases of normal (between 1999 and 2013) were recovered
from the archives of the Korea Cancer Center Hospital.
Tissue sections were deparaffinized, rehydrated, exposed
to antigen retrieval in antigen retrieval buffer, incubated
with 3% hydrogen peroxide and non-specific binding was
blocked using bovine serum albumin. These sections were
incubated with mouse monoclonal anti-PAX8 antibody
(1:400; Abcam) overnight at 4 °C, and then incubated with
biotinylated secondary antibody bound to a streptavidin–
horseradish peroxidase complex. The bound antibody was
distinguished using 3,3-diaminobenzidine and the sectionswere counterstained with hematoxylin, dehydrated and
mounted. All sections were recorded by individual
pathologists.
Immunofluorescence
For immunofluorescence, cells were fixed with 4% para-
formaldehyde and permeabilized with 0.1% Triton X-100
in PBS. Afterwards, cells were incubated with the PAX8
(anti-mouse, 1:200), NIS (anti-rabbit, 1:200) primary
antibodies in a solution of PBS with 1% bovine serum
albumin and 0.1% Triton X-100 at 4 °C overnight.
Next day, staining was visualized using anti-rabbit or
anti-mouse Alexa Flour 488 and anti-rabbit or anti-
mouse Alexa Flour 546 antibodies, and cells nuclei
were counterstained using 4,6-diamidino-2-phenylin-
dole (DAPI; Sigma). Stained cells were imaged with a
confocal fluorescence microscope (Nikon).
Flow cytometry
To examine the PAX8 positive cell population with
respected experiments, the LDR-exposed cells were fixed
with 2% paraformaldehyde and permeabilized with 90%
methanol as suggested by manufacturer’s protocol. Then,
these cells were labeled with an anti-PAX8 antibody. A
respective control was also prepared and tested for each
sample. The percentage of PAX8 positive cells were de-
termined using PE (Alexa-flour488) and was analyzed
using a BD FACSVerse cytometer and the FACS suite
software.
Thyroid stimulating hormone receptor (TSHR) ELISA assay
For TSHR determination, cell culture supernatant/blood
serum was collected as desired time points in each ex-
periment using colorimetric TSH receptor ELISA kit (LS
biosciences, LS-F12873). All assay steps were performed
according to kit manual instructions. This assay utilizes
an antibody specific for Human TSH coated on a
96-well plate. The intensity of the color is measured at
450 nm using an ELISA plate reader.
In vitro iodine uptake assay
Briefly, three days after cell seeding in 96-well cell cul-
ture plate, BCPAP cells formed approximately 75–80%
confluency and assay procedure was adopted from previ-
ous report [28].
Soft agar and sphere formation assays
For cellular transformation studies, we performed soft
agar colony assays and sphere forming assays. To ob-
serve anchorage independent growth, a cell suspension
(2 × 104 cells) was suspended in 0.4% agar in growth
medium and seeded in triplicate in 60-mm dishes
pre-coated with 0.8% agar in growth medium and incu-
bated at 37 °C with 5% CO2. After 16 days, colonies were
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fields and expressed as means of representative of two
independent experiments. For tumor sphere assays, cells
were plated as single-cell suspension in ultralow attach-
ment 6-well plates and grown in serum free DMEM/F12
medium supplemented with 20 μl ml− 1 B27 (Invitrogen),
20 ng ml− 1 EGF and 20 ng ml− 1 bFGF. Fresh media
(300 μl) was added every 3 days. At day 7, tumor spheres
were counted and photographed. All sphere and colony
formation assays were performed in triplicate.
Animal experiments
To make an orthotopic model of thyroid carcinoma, NSG
male mice (8–10 weeks old) Jackson Laboratories, Bar Har-
bor, ME, USA) were used according to previously estab-
lished method [29]. Housing and all experimental animal
procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) of the Center for Laboratory
Animal Sciences, the Medical Research Coordinating Cen-
ter, and the HYU Industry-University Cooperation Founda-
tion. We used stable N-thy ori-3-1 thyroid cells (Mock and
BRAF-untreated and LDR-treated) for animal experiment
and 2.5 × 105 cells/mouse (right side of thyroid gland) times
the number mice injecting. Mice were sacrificed 25 days
after cell injection and serum plasma were collected for
TSHR Elisa assay. Injected thyroid glands were also excised
for further experiments.
Statistical analysis
All experimental results are represented as the mean ±
standard deviation (S.D.) of at least three independent
tests. The statistical analysis was performed using the
parametric Student’s t-test to check the significance
levels. Levels of significance are indicated as *p < 0.05;
**p < 0.01; and ***p < 0.001.
Results
BRAF mutation induces hypothyroidism in thyroid cancer
To determine the BRAF expression pattern in human thy-
roid tumors, we screened BRAF expression in normal and
cancerous thyroid tissues using publically available GENT
database [30]. Database profiling revealed that thyroid tu-
mors demonstrated increased BRAF expression compared
to normal thyroid tumors (Fig. 1a). Moreover, the cancer
genome atlas (TCGA) analysis [31] shows high BRAF mu-
tation rate in PTC compared to FTC tumors (Fig. 1b).
Since BRAFV600E accounts for > 85% of BRAF mutations
in thyroid carcinomas as described previously [9], we
evaluated the BRAFV600E expression in human thyroid
cancer cells. As shown in Fig. 1c, BRAFV600E mRNA
levels were significantly higher in ATC (SNU-80, 850-5C)
and PTC (SNU-790, BCPAP) as compared to wild type
(BHP 10–3) and normal thyroid follicular epithelial cells
(N-thy ori-3-1). It has been shown earlier that lower levelsof serum TSH owing to severe hypothyroidism in
BrafV600E-induced thyroid cell models [32, 33]. Ac-
cordingly, when we analyzed TSHR levels in PTC and
ATC cells, we observed that TSHR levels were lower
in these cells as compared to normal thyroid follicular
N-thy ori-3-1 cells (Fig. 1d). High levels TSHR signal-
ing requires to upregulate NIS expression and iodide
uptake in differentiated thyroid cancer cells [34]. We
sought to investigate the NIS expression in BRAF mu-
tated thyroid cells. Likewise, BRAFV600E mutated as
well as wild type thyroid cancer cells demonstrated rela-
tively low expression of NIS as well as PAX8 (direct regu-
lator of NIS) compared to normal cells (Figs. 1e & f). In
addition, PTC tumors shows lower PAX8 expression
which have BRAFV600E mutation (Fig. 1g). TCGA database
further revealed that PAX8 is negatively co-related in
BRAF mutated thyroid tumors (Fig. 1h). To detect BRAF
mutation consequences on thyroid cells, we transformed
normal N-thy ori-3-1 cells with BRAFV600E mutation ex-
pression vector. A significant induction in thyroid cellular
transformation was observed in N-thy ori-3-1 transformed
cells as visualized by soft agar colony formation and
sphere forming assays (Figs. 1i-j). These studies confirmed
that BRAFV600E mutation suppresses the iodine metaboliz-
ing gene levels and induce cellular transformation in thy-
roid carcinoma cells, prompting us to explore the role of
LDR in the BRAF-induced cellular transformation at
initiation levels.
LDR inhibits BRAF-driven cellular transformation and
rescues repression of iodine-metabolizing gene
expression responsible for thyroid cancer initiation
We have previously shown that LDR have potential to re-
duce cancer progression at fractionated (1cGyx10) or single
doses (0.1Gy or 10cGy) [17, 18]. In accordance, we con-
firmed that LDR diminishes the growth of 850-5C, BCPAP
as well as N-thy ori-3-1 BRAFV600E transformed thyroid
cancer cells at both doses (Additional file 1: Figure S1A).
Therefore, we decided to use these doses to interrogate
whether LDR is capable to reduce cellular transformation
in BRAF transformed thyroid cells. Interestingly, LDR sig-
nificantly suppresses colony formation in N-thy ori-3-1
cells at both doses fractionated as well as single doses
(Fig. 2a). A comparable effect was also seen in 850-5C and
BCPAP thyroid cancer cells after LDR exposure as con-
firmed by sphere forming assays (Fig. 2b). These find-
ings lead us to investigate whether LDR can increase
expression of iodine-metabolizing genes in normal
N-thy ori-3-1 cells after BRAFV600E mutation respon-
sible for thyroid carcinogenesis. Interestingly, LDR re-
stores the TSHR, TG, NIS, PAX8, TTF-1 and TTF-2
mRNA levels in normal thyroid BRAF-transformed
cells (Fig. 2c), whereas HDR was fail to increase expres-
sion of these genes N-thy ori-3-1 BRAF transformed
Fig. 1 BRAF is highly expressed in thyroid cancer. a Analysis of BRAF expression in thyroid cancer among various cancer subtypes through publically
available GENT database tool. b Evaluation of BRAF mutation frequency in papillary and follicular thyroid carcinoma using TCGA database. c Relative
BRAF mRNA expression across normal follicular thyroid (N-thy ori-3-1), BRAF wild-type (BHP 10–3) and BRAF mutated-type (SNU-80, 850-5C, SNU-790,
BCPAP) thyroid cancer cell lines. d ELISA assay for determination of TSHR levels in thyroid cells. e, f NIS and PAX8 mRNA expression in several thyroid
cell lines respectively. g Immunohistochemistry for PAX8 expression in normal and PTC tumors as indicated in panels. h Co-relation studies of BRAF and
PAX8 mRNA expression using TCGA database. PAX8 was negatively co-related with BRAF expression. i, j Soft agar colony and tumor sphere formation
assay in BRAFV600E mutated normal N-thy ori-3-1 transformed thyroid cells. Each experiment represents the mean of at least two independent set of
experiments. β-actin was used as a control for normalization. Scale bar = 100 μm; *p < 0.05, **p < 0.001, and ***p < 0.0001
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Similar results were obtained in in BCPAP thyroid cancer
cells at a dose of 2Gy HDR (Additional file 1: Figure S2B).
Comparable observations were also seen on thyroid
iodine-metabolizing genes in case of 850-5C (ATC) and
BCPAP (PTC) cell lines after LDR exposure (Fig. 2d). SincePAX8 is critical for NIS targeting, responsible for iodine
uptake, we performed FACS analysis to check PAX8 posi-
tive population. A significant increase in PAX8 positive
cells were detected in LDR exposed BRAF-transformed
cells when compared to BRAF transformed cells without
LDR treatment (Fig. 2e). Consistent with these findings, we
Fig. 2 LDR blocks cellular transformation through upregulating iodine-metabolizing gene expression in BRAF-transformed thyroid cells. a Soft agar colony
formation in BRAFV600E transformed N-thy ori-3-1 cells after fractionated (0.01Gy× 10) and single dose (0.1Gy) of LDR. b Quantification of tumor sphere
formation in 850-5C and BCPAP thyroid cancer cells after fractionated (0.01Gy × 10) and single dose (0.1Gy) of LDR. c Relative mRNA expression of thyroid
iodine metabolizing genes in BRAFV600E transformed N-thy ori-3-1 cells after fractionated (0.01Gy × 10) dose of radiation. d Relative mRNA expression of
thyroid iodine metabolizing genes in 850-5C and BCPAP cells after fractionated (0.01Gyx10) and single dose (0.1Gy) of LDR. e Flow cytometry analysis of
PAX8 positive cells in BRAFV600E transformed N-thy ori-3-1 cells after fractionated (0.01Gyx10) dose of radiation. f Immunofluorescence for NIS and PAX8
expression levels in 850-5C and BCPAP thyroid cancer cells after fractionated (0.01Gyx10) and single dose (0.1Gy) of LDR. g A non-radioactive iodine assay
was performed in BCPAP thyroid cancer cells after fractionated (0.01Gyx10) and single dose (0.1Gy) of LDR. β-actin was used as a control for normalization.
Scale bar = 50 μm; *p< 0.05, **p< 0.001, and ***p< 0.0001
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proves NIS (membrane localization) expression in LDR-
exposed BCPAP cells (Fig. 2f ). Interestingly, iodine up-
take assay showed that LDR can restore iodine uptake
in BCPAP cancer cells as seen by Fig. 2g. Taken to-
gether, these data support that LDR actively restores
BRAF-dependent repression of thyroid iodine metabol-
izing genes in thyroid cells at the initiation phase of
cancer progression.PAX8 upregulation is critical in decreased cellular
carcinogenesis
As mentioned earlier, PAX8 is critical for the cellular differ-
entiation, being a direct mediator of the thyroid-specific
expression of the genes expressed in the thyroid cell type
[23]. We questioned whether LDR can also target PAX8
signature genes upregulation as described previously [35].
Real time PCR analysis showed that LDR treatment po-
tently upregulated the PAX8 target signature genes in
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we observed above that LDR increases PAX8 expression
effectively, we wanted to further examine whether PAX8
upregulation is critical in maintenance of thyroid func-
tional state. To this end, we checked NIS and TG expres-
sion after PAX8 knock-down in LDR-exposed cells, which
are chief determinants of thyroid iodine metabolizing. Data
showed that PAX8 silencing abolished the effect of LDR on
NIS and TG upregulation in 850-5C cancer cells (Fig. 3b).
Likewise, PAX8 knockdown also harbored LDR-mediated
suppression of BRAF-induced cellular transformation in
850-5C cancer cells as observed by sphere forming and soft
agar colony forming assays (Figs. 3c & d). These ob-
servations clearly suggest that LDR could effectively
inhibit the cellular transformation of BRAF-mutated
cells potentially through the induction of PAX8 and
its target genes.
Loss of miR-330-5p leads to PAX8 upregulation by LDR
and improve NIS/TG expression
To carry out an in-depth analysis of the LDR-mediated
PAX8 induction, we screened putative PAX8 targeting
microRNAs (miRNAs) using online available prediction
tools TargetScan [36] and miRDB [37] and miRANDA [38].
These different tools have been developed for prediction of
miRNA-mRNA interactions. Most well-characterized func-
tion of miRNAs to downregulate gene expression by bind-
ing to complementary sites within transcript sequences and
suppress their translation and eventually stimulate their
degradation [39]. To determine whether LDR may driveFig. 3 PAX8 suppressed thyroid carcinogenesis after LDR exposure. a Analy
ori-3-1 cells after fractionated (0.01Gyx10) dose of radiation. b qPCR analysi
after PAX8 silencing. c, d Sphere and colony formation was determined in
used as a control for normalization. *p < 0.05, **p < 0.001, and ***p < 0.0001the PAX8 restoration in thyroid carcinoma cells through
the inhibition of miRNAs, we assessed PAX8 targeting
miRNAs as above mentioned techniques. We found that
miR-144-3p and miR-330-5p were most prominent candi-
date for PAX8 targeting (Fig. 4a). To confirm miRNAs
identified by prediction tools, we checked further PAX8
levels in 850-5C thyroid carcinoma cells after miR-144-3p
and miR-330-5p inhibitor treatment. PAX8 levels were
significantly higher in 850-5C after these miRNAs silencing
(Fig. 4b & Additional file 1: Figure S3A), suggesting the in-
volvement of these miRNAs in LDR-induced PAX8 expres-
sion. In BRAFV600E transformed N-thy ori-3-1 thyroid cells,
the expression of miR-144-3p and miR-330-5p were greatly
reduced as compared to non-irradiated one (Fig. 4c). Fur-
thermore, the expression of these miRNAs was also mark-
edly decreased in the 850-5C and BCPAP cancer cells after
LDR treatment (Fig. 4d), whereas HDR stimulated marked
induction in miR-144-3p and miR-330-5p expression in
both cell types (Additional file 1: Figure S3B). Exogenous
treatment with miR-330-5p mimetics abolished the effect
of LDR on PAX8 induction in 850-5C and BCPAP cells
more prominently, however this effect was negligible in
case of miR-144-3p in both cells (Figs. 4e, f & Additional
file 1: Figure S3C). As expected, immunofluorescence
staining showed the similar effects on BCPAP cells after
miR-330-5p and miR-144-3p overexpression in re-
sponse to radiation (Fig. 4g). In addition, FACS analysis
confirmed that LDR-mediated PAX8 induction was inter-
rupted by miR-330-5p mimics treatment in BCPAP cancer
cells (Fig. 4h). Of note, ELISA assay shows recovered TSHRsis of PAX8 target signature genes in BRAFV600E transformed N-thy
s of NIS and TG expression in LDR-treated 850-5C thyroid cancer cells
850-5C cancer cells in same conditions as shown in B. β-actin was
Fig. 4 miR-330-5p targets PAX8 and is downregulated by LDR. PAX8 suppressed thyroid carcinogenesis after LDR exposure. a Venn diagram
showing the PAX8 targeting miRNAs predicted by miRNA prediction tools as mentioned in panels. b Determination of PAX8 mRNA after anti-miR-
144-3p and anti-miR-330-5p treatment in 850-5C thyroid cancer cells. c, d qPCR analysis of miR-144-3p and miR-330-5p levels in BRAFV600E
transformed N-thy ori-3-1, BRAF-mutated 850-5C and BCPAP thyroid cancer cells after fractionated (0.01Gyx10) and single dose (0.1Gy) of LDR
respectively. e, f miR-144-3p and miR-330-5p mimics were treated in LDR-exposed 850-5C and BCPAP cells and PAX8 levels were detected by
western blot and qPCR analysis respectively. g Immunofluorescence of PAX8 levels in LDR-treated BCPAP thyroid cancer cells after miR-144-3p
and miR-330-5p mimics transfection. h FACS analysis for PAX8 expression in LDR-treated BCPAP cells after miR-330-5p transfection. i, j TG, NIS
mRNA levels and soft agar colony formation was analyzed in LDR-treated BCPAP thyroid cancer cells after miR-330-5p mimetics transfection.
k TSHR levels were detected by ELISA assay in cell supernatants of LDR-treated BCPAP thyroid cancer cells in similar conditions as used in H.
β-actin was used as a control for normalization. *p < 0.05, **p < 0.001, and ***p < 0.0001
Kaushik et al. Cell Communication and Signaling           (2019) 17:12 Page 8 of 13levels in normal N-thy ori-3-1 transformed cells after LDR
(Additional file 1: Figure S1B). Therefore, consistent with
these studies, miR-330-5p overexpression abolished the
effect on TG, NIS, colony formation and TSHR levelsin BCPAP cells in response of LDR (Figs. 4i-k). Hence,
we hypothesized that LDR-mediated induction of iodine-
metabolizing genes could be explained by the inhibition of
miRNA pathway in thyroid cancer cells.
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essential for thyroid malfunction decreased by LDR
Since, recently Lesinski suggested that targeting STAT3
could overcome BRAF-resistance tumors [40], to identify
signaling mechanism underlying LDR deregulated miR-
NAs, we first checked phosphorylation status of JAK/
STAT pathway. We found that JAK2 and STAT3 were
reduced after LDR treatment in both 850-5C and
BCPAP cancer cells (Fig. 5a). Next, to confirm the role
of STAT3 in LDR-decreased miRNAs expression, weFig. 5 LDR reduces activation of JAK2/STAT3 and downregulates miR-330-5p
JAK2, STAT3, STAT5 was observed by western blot analysis in 850-5C and BCP
specific gene (PAX8, NIS and TG) levels in STAT3 overexpressing BCPAP thyroid
expression in STAT3 overexpressing BCPAP cells after LDR treatment. e, f Soft
same conditions as shown in D. Scale bar = 100 and 50μm. β-actin was usedoverexpressed BCPAP cells with STAT3 expression vec-
tor. Noticeably, forced expression of STAT3 blocked the
LDR-effect on miR-330-5p downregulation in BCPAP
thyroid cells (Fig. 5b). Subsequently, PAX8, NIS and TG
were also reduced after STAT3 overexpression in BCPAP
cells (Figs. 5c & d). Finally, we confirmed these findings
on cellular transformation studies in thyroid cells. We
found that exogenous expression of STAT3 abrogated
the effect of LDR on thyroid carcinogenesis as shown
by soft agar colony formation and sphere formationlevels to reduce cellular transformation. a Phosphorylation status of JAK1,
AP thyroid cancer cells. b, c qPCR analysis for miR-330-5p and thyroid
cancer cells after LDR treatment. d Immunocytochemistry for NIS
agar colonies and sphere formation was determined in BCPAP cells in
as a control for normalization. *p < 0.05, **p < 0.001, and ***p < 0.0001
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investigate how LDR can suppress STAT3 activation in
thyroid cancer cells. While the suppressor of cytokine sig-
naling (SOCS) proteins are known as negative regulators of
JAK/STAT signaling pathways [41], we screening SOCS
family proteins in LDR-exposed BCPAP thyroid carcinoma
cells. Among all tested SOCS members, SOCS3 and SOCS4
were notably increased in response to radiation (Additional
file 1: Figure S3D). Taken together, these data strongly
support a mechanism by which LDR actively repressesFig. 6 LDR reduces thyroid carcinogenesis in Orthotopic mice xenografts. a
and LDR-treated). b qRT-PCR analysis of TSHR, NIS and PAX8 mRNA express
were detected by ELISA assay in blood serum of control and LDR-treated B
thyroid gland sections for NIS, TG, BRAF and PAX8 expressionSTAT3-dependent miR-330-5p in BRAF-mutated thyroid
cells, thereby upregulating PAX8 and related target genes.
Expression of thyroid metabolizing genes are
dramatically restored in BRAF-mutant mice model
As in vitro experiments revealed that LDR can improve
thyroid metabolism regulating genes in thyroid cancer
cells, and these cells also reduce transformation process.
We then considered whether exposure of LDR might
suppress carcinogenesis process in thyroid xenograftPictorial presentation of thyroid orthotopic mice models (Untreated
ion in LDR-treated and untreated thyroid gland tissues. c TSHR levels
CPAP thyroid cancer cells. d Hematoxylin Eosin (HE)/IHC images of
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mice model and injected BRAFV600E thyroid cells in
thyroid gland of mice. Upon sacrifice, we detected that
thyroid gland size is much smaller in LDR exposed BRAF-
mutated group compared to only BRAF injected group
(Fig. 6a). Remarkably, levels of TSHR, PAX8 and NIS also
increased in LDR-exposed BRAF mice group (Figs. 6b-d).
These data further establish LDR acts as a suppressor for
thyroid carcinogenesis in mice and, thereby indicate a
promising candidate in radiation biology.Discussion
Generally, the diagnosis for PTCs is suitable unless the
tumor presents a well or poorly differentiated phenotype. It
is believed that dedifferentiation is correlated with molecu-
lar alterations of proteins that permit the thyrocytes to
concentrate the iodine, which render the tumor refractive
to radioiodine treatment [22]. Aberrant activation of
BRAFV600E mutation is accompanying with the loss of
radioiodine uptake and therapy failure in PTC. Reliably,
BRAFV600E mutation is highly predominant (80–90%) in re-
current radioiodine-refractory PTC/ATC patients [42, 43],
as comparison with the lower occurrence of BRAFV600E
mutation (40%) in primary PTC [9]. Several studies have
demonstrated an association of BRAFV600E mutation with
reduced expression of thyroid iodide-metabolizing genes
namely NIS, TSHR, TG in thyroid cancer and induces
hypothyroidism [19, 44]. Moreover, Liu et al. showed that
BRAFV600E is directly involved in impairment of theFig. 7 LDR suppresses the thyroid cancer carcinogenesis through STAT3-miR
degrades the PAX8 mRNA levels, thereby blocks its activity to NIS, TG and TSH
miRNAs expression and eventually recovers the PAX8 activity on its target genexpression of almost these genes using a MEK inhibitor
[33]. Consistent with this studies, we also identified that
PAX8 has lower expression in PTC and ATC patients hav-
ing BRAFV600E mutation (Fig. 1g).
Molecular events leading to the loss of thyroid differ-
entiation in thyroid cancer draws much attention, espe-
cially loss of NIS expression. NIS is required for the
active transport of iodide into the thyroid cells, and for
the diagnosis and therapeutic management of thyroid
cancer patients treated with radioiodine. We determine
for the first time that LDR critically enhanced PAX8 ex-
pression levels in PTC and ATC expressing BRAFV600E
mutant. PAX8 is a transcription factors that controls the
transcription of NIS, is essential for the thyroid gland
development and for maintaining the differentiated state
in the normal thyroid gland [45]. We also show that
PAX8 modulated NIS expression in thyroid cancer after
LDR exposure in thyroid cells. PAX8 overexpression
facilitate NIS expression on plasma membrane and im-
prove its localization (data not shown). To figure out
how the LDR-mediated induction of PAX8 involved in
thyroid-specific activation of the NIS and TG gene, we
took advantage of the miRNA-based approach. Interest-
ingly, the results obtained with the prediction online
tools indicate that the miR-144-3p and miR-330-5p con-
taining the already known PAX8 targeting sites could be
involved in LDR function. In real time PCR assays, LDR
treatment downregulated both miRNAs expression very
efficiently, whereas the HDR responded poorly to these
miRNAs, showing an activation. On the contrary, miR--330-5p axis. During thyroid cell malfunction, miR-144-3p/miR-330-5p
R promoters. However, LDR treatment decreases the PAX8 targeting
e promotes to improve thyroid cell function in cancer cells
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NIS, TG and colony formation in PTC (Figs. 4i-j). As
miRNAs expression decreases in response to LDR rather
than HDR, we identified upstream molecule which can
be affected through LDR. The results emphasize that
JAK2/STAT3 activation was harbored after LDR in PTC/
ATC (Fig. 5a). The STAT3 overexpression state contra-
dicted LDR function in maintenance of PAX8, NIS, TG
gene expression that may contribute to cellular trans-
formation (Figs. 5c & f). Despite the sensitivity of LDR
to BRAF-induced cellular transformation in thyroid
cells, their BRAF expression levels were not downregu-
lated by LDR from those detected in BRAFV600E cells. It
could be assumed that some other pathway is intricate
in STAT3 activation rather than BRAF phosphorylation.
To resolve this question, we measured the SOCS family
proteins, whose expression negatively regulate JAK/STAT
signaling after LDR treatment. In doing so, we found that
SOCS3 and SOCS4 were majorly induced in LDR-treated
PTC cells (Additional file 1: Figure S3D). In addition, Klei-
man et al., suggested that the marked reduction of TSHR
co-operates with oncogenic BRAF induced dysregulation of
thyroid development [32] and TSHR signaling is required
for expression of a subset of thyroid-specific genes during
development [46]. Our data indicated LDR effectively re-
covered TSHR levels in thyroid carcinoma cells (Additional
file 1: Figure S1B), perhaps decreasing STAT3-miRNA axis
route accounting for the high undifferentiated phenotype.
Conclusion
In this study, we identified a signaling regulatory network
in LDR-mediated PTC carcinogenesis suppression that is
responsible in BRAFV600E-mutated thyroid cancer pheno-
typic transformation. Our studies characterized LDR can
act as a repressor of BRAF induced STAT3-mediated
miR-330-5p axis that eventually upregulates thyroid me-
tabolizing genes expression through PAX8 induction,
unveiling a regulatory circuit that defines the undifferenti-
ated phenotype in PTC (Fig. 7). These studies provide
LDR could be beneficial in alteration in these molecules
that governs BRAFV600E-dependent cellular transform-
ation in thyroid carcinoma cells and constitute potential
new therapeutic targets for thyroid patients.
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